Heffernan Michael Thomas 4

What Happened
Michael Thomas Heffernan, a director of enGene Therapeutics, received a grant of a derivative security: an option award covering 31,000 shares. The reported acquisition price is $0.00 (the Form 4 lists the grant as a derivative award, not an open-market purchase or sale). This is a compensation grant rather than a sale or cash purchase.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-17.
• Reported amount: option award for 31,000 shares; reported price $0.00 (derivative).
• Vesting note: The option vests in full on the earlier of (i) the first anniversary of the vesting commencement date (vesting commencement date was June 9, 2026, so full vesting by June 9, 2027) or (ii) the registrant’s 2027 annual meeting of shareholders (Footnote F1).
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: Form 4 was filed the day after the transaction; no late filing flag indicated.

Context
This was an option/award grant (a compensation event) rather than a purchase or sale — the insider does not immediately receive tradable shares until vesting and any exercise requirements are met. Such grants are common as director compensation and do not by themselves signal buying or selling intent.